Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the platform to its strategic partners and licensing customers. Abgenix was ...
More >>
Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the platform to its strategic partners and licensing customers. Abgenix was acquired by Amgen for cash in 2006.
<< Less